INCA-33890, a novel bispecific antibody targeting PD-1 and TGF-ꞵR2

May 8, 2023

Researchers from Incyte Corp. presented preclinical characterization of a novel bispecific antibody, INCA-33890, targeting PD-1 and transforming growth factor-β receptor type-2 (TGF-βR2).

BioWorld Science Conferences Cancer Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for April 6, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...